Skip to main content
. 2023 Jun 20;11:e15586. doi: 10.7717/peerj.15586

Figure 2. Effect on cell viability.

Figure 2

MCF7 human breast cancer cells were treated with different concentrations from 0.1 to 100 µM for 24, 48, and 72 h with: (A) 7-hydroxy-3,4-dihydrocadalene, (B) 7-(phenylcarbamate)-3,4-dihydrocadalene, (C) 7-(phenylcarbamate)-cadalene Moreover, (D) (Z)-4-hydroxytamoxifen at 5, 10, 20, and 40 µM was added to MCF7 for 24 h and (E) human embryonic cells from kidney (HEK 293, control cells) were treated with 7-hydroxy-3,4-dihydrocadalene for 72 h. MTT assay was performed. Results are shown as means ± SD of at least three independent experiments (*P < 0.05, **P < 0.01 and ****P < 0.0001 vs. 24 h; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. 48 h).